AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29917215 — intervention group
Group type: COMPARATOR
Intervention: Ferrous gluconate (FG), 80 mg of FG per day for 30 days
Number of subjects: 50
Study 27889710 — intervention group
Group type: EXPERIMENTAL
Intervention: IV maintenance therapy with phenobarbitone
Number of subjects: 152
Study 27889710 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 152
Study 27889710 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (phenobarbitone and placebo)
Number of subjects: 152
Study 24848391 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtenon anesthesia
Number of subjects: 304
Study 24848391 — intervention group
Group type: COMPARATOR
Intervention: Peribulbar anesthesia
Number of subjects: 304
Study 23796152 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartWare Ventricular Assist System
Number of subjects: 332
Study 19482306 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted placement
Number of subjects: 77
Study 19482306 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 77
Study 18794651 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment (specifics not provided)
Number of subjects: 1627
Study 16177618 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 KKW (4 kcal(‐1).kg(‐1).wk(‐1))
Number of subjects: 111
Study 16177618 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 KKW (8 kcal(‐1).kg(‐1).wk(‐1))
Number of subjects: 111
Study 16177618 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 KKW (12 kcal(‐1).kg(‐1).wk(‐1))
Number of subjects: 111
Study 12732934 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoluminal stenting after tracheal lumen re-establishment
Number of subjects: 16
Study 11789204 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotaxic drainage and orally taken Zhuyu Xiaozhong mixture (ZYXZM)
Number of subjects: 61
Study 11789204 — intervention group
Group type: COMPARATOR
Intervention: Stereotaxic drainage alone
Number of subjects: 61
Study 8651549 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU plus levamisole (SWOG 8591)
Number of subjects: 0
Study 8651549 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU, whole‐abdominal radiation, and tumor boost
Number of subjects: 0
Study 8651549 — intervention group
Group type: COMPARATOR
Intervention: Observation group
Number of subjects: 0
Study 8651549 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU plus levamisole
Number of subjects: 0
Study 1531464 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal nafarelin 200 micrograms two times a day
Number of subjects: 307
Study 1531464 — intervention group
Group type: COMPARATOR
Intervention: Oral danazol 200 mg three times a day
Number of subjects: 307
Study 6514178 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 20
Study 6514178 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 20
Study 6514178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31829252 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex intervention consisting of a blended training program, local interdisciplinary meetings, and interdisciplinary case conferences.
Number of subjects: 24
Study 31829252 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary approach of the intervention.
Number of subjects: 24
Study 31829252 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with implementation and perceived impact.
Number of subjects: 24
Study 31829252 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall implementation and satisfaction rates.
Number of subjects: 24
Study 29369090 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-item self-report instrument for physical activity
Number of subjects: 537
Study 26800903 — intervention group
Group type: EXPERIMENTAL
Intervention: Hep‐Net intervention (algorithm‐based, real‐time tailored feedback and recommendations for behavior change)
Number of subjects: 235
Study 26800903 — intervention group
Group type: COMPARATOR
Intervention: Usual care (standard counseling by syringe exchange staff)
Number of subjects: 235
Study 26800903 — intervention group
Group type: EXPERIMENTAL
Intervention: Hep‐Net intervention
Number of subjects: 235
Study 26800903 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 235
Study 24915052 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 30 mg plus Valsartan 80 mg (N30+V80)
Number of subjects: 391
Study 24915052 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 60 mg (N60)
Number of subjects: 391
Study 24915052 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 160 mg (V160)
Number of subjects: 391
Study 22168345 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of alcohol per kilogram of body mass
Number of subjects: 10
Study 22168345 — intervention group
Group type: COMPARATOR
Intervention: Non-alcoholic control beverage
Number of subjects: 10
Study 20224514 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentration-controlled mycophenolate mofetil (MMF) dosing based on mycophenolic acid (MPA) exposure
Number of subjects: 130
Study 20224514 — intervention group
Group type: COMPARATOR
Intervention: Fixed-dose mycophenolate mofetil (MMF)
Number of subjects: 130
Study 20224514 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentration-controlled mycophenolate mofetil (MMF) dosing
Number of subjects: 130
Study 20224514 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Concentration-controlled and Fixed-dose)
Number of subjects: 130
Study 17428615 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking Consequences Questionnaire‐Adult (SCQ‐A) Weight Control scores
Number of subjects: 385
Study 17428615 — intervention group
Group type: EXPERIMENTAL
Intervention: SCQ‐A Weight Control scores
Number of subjects: 385
Study 17428615 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported weight gain at previous attempts
Number of subjects: 385
Study 16146495 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement Energy Index (MEI) for patients with cervical dystonia
Number of subjects: 6
Study 16146495 — intervention group
Group type: COMPARATOR
Intervention: Movement Energy Index (MEI) for controls
Number of subjects: 6
Study 16146495 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement Energy Index (MEI) for patients
Number of subjects: 6
Study 12442631 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10193967 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency‐doubled Q‐switched Nd:YAG laser (532 nm)
Number of subjects: 20
Study 10193967 — intervention group
Group type: COMPARATOR
Intervention: 35% TCA
Number of subjects: 20
Study 8547373 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Barthel and Mini-mental State Examination scores
Number of subjects: 0
Study 1433451 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine alone (3 doses at 0, 1, 2 months)
Number of subjects: 109
Study 1433451 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine + HBIG (3 doses at 0, 1, 2 months)
Number of subjects: 109
Study 1433451 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vaccination)
Number of subjects: 109
Study 1433451 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine alone
Number of subjects: 109
Study 1433451 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine + HBIG
Number of subjects: 109
Study 2998663 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 14
Study 2998663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 30067456 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week teacher-led intervention to improve actual motor competence (MC)
Number of subjects: 171
Study 30067456 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned in the abstract)
Number of subjects: 171
Study 30067456 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week teacher-led intervention
Number of subjects: 171
Study 28370973 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days of antibiotic treatment according to bacteriogram sensitivity
Number of subjects: 27
Study 28370973 — intervention group
Group type: COMPARATOR
Intervention: Observational group (no treatment)
Number of subjects: 27
Study 27185197 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab 1000 mg on days 1 and 8 of the first cycle and day 1 of the second and third cycles (O-ESHAP)
Number of subjects: 62
Study 24645632 — intervention group
Group type: EXPERIMENTAL
Intervention: CMM (invasive cutaneous malignant melanoma)
Number of subjects: 52869
Study 24645632 — intervention group
Group type: EXPERIMENTAL
Intervention: SCC (squamous cell carcinoma)
Number of subjects: 52869
Study 24645632 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent skin cancers
Number of subjects: 52869
Study 24645632 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-skin cancers (oral, lung, colon, breast, prostate, thyroid, leukemia, lymphoma, central nervous system)
Number of subjects: 52869
Study 24645632 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors
Number of subjects: 52869
Study 24645632 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental cancer
Number of subjects: 52869
Study 22620487 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Number of subjects: 19
Study 22620487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 20976845 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially covered sphincterotome
Number of subjects: 387
Study 20976845 — intervention group
Group type: COMPARATOR
Intervention: Uncovered sphincterotome
Number of subjects: 387
Study 20976845 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 387
Study 18599956 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (N=733)
Number of subjects: 733
Study 18599956 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (N=106)
Number of subjects: 733
Study 18599956 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 733
Study 16162716 — intervention group
Group type: EXPERIMENTAL
Intervention: PiKo‐1 device
Number of subjects: 38
Study 16162716 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirotel device
Number of subjects: 38
Study 16162716 — intervention group
Group type: COMPARATOR
Intervention: Mini‐Wright Peak‐Flow Meter
Number of subjects: 38
Study 12474709 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin administration
Number of subjects: 0
Study 9629050 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofix rods and screws
Number of subjects: 41
Study 9629050 — intervention group
Group type: COMPARATOR
Intervention: Standard A.O. fixation
Number of subjects: 41
Study 7939146 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetazoline spray
Number of subjects: 5
Study 7939146 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetazoline solution
Number of subjects: 5
Study 7939146 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 5
Study 7939146 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 5
Study 3219315 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate meal
Number of subjects: 0
Study 3219315 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 0
Study 3219315 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein meal
Number of subjects: 0
Study 3219315 — intervention group
Group type: EXPERIMENTAL
Intervention: Added sodium chloride
Number of subjects: 0
Study 3219315 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium chloride
Number of subjects: 0
Study 3219315 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-protein meals
Number of subjects: 0
Study 3219315 — intervention group
Group type: EXPERIMENTAL
Intervention: Meals containing 220 g protein/kg dry weight
Number of subjects: 0
Study 29673108 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide (25 mg/day)
Number of subjects: 133
Study 29673108 — intervention group
Group type: COMPARATOR
Intervention: Lenalidomide plus Dexamethasone (25 mg/day and 40 mg/week)
Number of subjects: 133
Study 29673108 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who achieved ≥PR but did not proceed into the phase 2 trial
Number of subjects: 133
Study 26667928 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load Slow Movement Squat Training (LST) - 50% one-repetition maximum (1-RM) load, 3 seconds for lowering/lifting without pause
Number of subjects: 16
Study 26667928 — intervention group
Group type: COMPARATOR
Intervention: Low-load Normal Speed (LN) - 50% 1-RM load, 1 second for lowering/lifting with 1-second pause
Number of subjects: 16
Study 24749983 — intervention group
Group type: EXPERIMENTAL
Intervention: Video intervention
Number of subjects: 803
Study 24749983 — intervention group
Group type: COMPARATOR
Intervention: Text intervention
Number of subjects: 803
Study 24749983 — intervention group
Group type: COMPARATOR
Intervention: Combination intervention
Number of subjects: 803
Study 23552127 — intervention group
Group type: EXPERIMENTAL
Intervention: Zofenopril 60 mg and ASA 100 mg
Number of subjects: 682
Study 23552127 — intervention group
Group type: COMPARATOR
Intervention: Ramipril 10 mg and ASA
Number of subjects: 682
Study 20663302 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure support level of 5 cm H2O
Number of subjects: 15
Study 20663302 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure support level of 15 cm H2O
Number of subjects: 15
Study 18402900 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-V (1 RV and 2 LV leads)
Number of subjects: 40
Study 18402900 — intervention group
Group type: COMPARATOR
Intervention: 2-V (1 RV and 1 LV lead)
Number of subjects: 40
Study 16450089 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (1,200 mg)
Number of subjects: 14
Study 16450089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 12834797 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweetened chewing gum
Number of subjects: 0
Study 12834797 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsweetened chewing gum
Number of subjects: 0
Study 12834797 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweet taste without chewing
Number of subjects: 0
Study 12834797 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweet taste with chewing
Number of subjects: 0
Study 12834797 — intervention group
Group type: COMPARATOR
Intervention: Control group (no gum)
Number of subjects: 0
Study 11029335 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-induced bronchoconstriction
Number of subjects: 10
Study 11029335 — intervention group
Group type: COMPARATOR
Intervention: Methacholine challenge
Number of subjects: 10
Study 11029335 — intervention group
Group type: COMPARATOR
Intervention: Allergen inhalation
Number of subjects: 10
Study 8930154 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (3.125, 12.5, 50 and 200 mg)
Number of subjects: 8
Study 8930154 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cocaine and hydromorphone
Number of subjects: 8
Study 8930154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8403955 — intervention group
Group type: EXPERIMENTAL
Intervention: Procainamide
Number of subjects: 46
Study 8403955 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 46
Study 2868964 — intervention group
Group type: EXPERIMENTAL
Intervention: Azodisal sodium
Number of subjects: 102
Study 2868964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 29673132 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine (10-20mg/day)
Number of subjects: 101
Study 29673132 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram
Number of subjects: 101
Study 27311415 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg calcium supplementation
Number of subjects: 65
Study 27311415 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 mg calcium supplementation
Number of subjects: 65
Study 27311415 — intervention group
Group type: COMPARATOR
Intervention: 500 mg calcium supplementation
Number of subjects: 65
Study 24972105 — intervention group
Group type: EXPERIMENTAL
Intervention: VIPP-TM (Video-feedback Intervention to promote Positive Parenting and Sensitive Discipline)
Number of subjects: 76
Study 24972105 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 76
Study 22855866 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 100 mg twice daily for 3 weeks, then 200 mg twice daily for 3 weeks
Number of subjects: 61
Study 22855866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 20727160 — intervention group
Group type: EXPERIMENTAL
Intervention: Wood smoke exposure (PM2.5 concentration of 224 ± 22 μg/m3)
Number of subjects: 19
Study 20727160 — intervention group
Group type: COMPARATOR
Intervention: Filtered air exposure
Number of subjects: 19
Study 18666493 — intervention group
Group type: EXPERIMENTAL
Intervention: iBond applied to lesions with sclerosis scale 1 and 2 (n=28)
Number of subjects: 105
Study 18666493 — intervention group
Group type: COMPARATOR
Intervention: SB applied to lesions with sclerosis scale 1 and 2 (n=26)
Number of subjects: 105
Study 18666493 — intervention group
Group type: EXPERIMENTAL
Intervention: iBond applied to lesions with sclerosis scale 3 and 4 (n=25)
Number of subjects: 105
Study 18666493 — intervention group
Group type: EXPERIMENTAL
Intervention: iBond applied with prior acid-etching to lesions with sclerosis scale 3 and 4 (n=26)
Number of subjects: 105
Study 16448252 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect bonding with antimicrobial varnish applied on etched enamel
Number of subjects: 60
Study 16448252 — intervention group
Group type: COMPARATOR
Intervention: Indirect bonding control group (no varnish)
Number of subjects: 60
Study 16448252 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct bonding with antimicrobial varnish mixed with Transbond MIP primer
Number of subjects: 60
Study 12818631 — intervention group
Group type: EXPERIMENTAL
Intervention: s.c. melagatran (1-3 mg bid) followed by oral ximelagatran (8-24 mg bid)
Number of subjects: 0
Study 12818631 — intervention group
Group type: EXPERIMENTAL
Intervention: s.c. melagatran (3 mg bid) followed by oral ximelagatran (24 mg)
Number of subjects: 0
Study 12818631 — intervention group
Group type: COMPARATOR
Intervention: s.c. dalteparin (5000 IU od)
Number of subjects: 0
Study 12818631 — intervention group
Group type: COMPARATOR
Intervention: s.c. enoxaparin (40 mg od)
Number of subjects: 0
Study 10353130 — intervention group
Group type: EXPERIMENTAL
Intervention: Biatrial synchronous pacing (BSP) via epicardial electrodes, initiated in AAI-Mode at a rate of 10 beats/min above the underlying rhythm (maximum 110 beats/min) for 3 days.
Number of subjects: 21
Study 10353130 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (control group with 9 patients).
Number of subjects: 21
Study 7546525 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-biocompatible membrane (cuprophane)
Number of subjects: 8
Study 7546525 — intervention group
Group type: EXPERIMENTAL
Intervention: High-biocompatible membrane (polyacrylonitrile)
Number of subjects: 8
Study 7546525 — intervention group
Group type: COMPARATOR
Intervention: Isolated hemodialysis (without ultrafiltration)
Number of subjects: 8
Study 7546525 — intervention group
Group type: COMPARATOR
Intervention: Ultrafiltration (with ultrafiltration)
Number of subjects: 8
Study 1773905 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of bacterial extracts over 16 weeks
Number of subjects: 0
Study 1773905 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular benzanthine penicillin
Number of subjects: 0
Study 6258375 — intervention group
Group type: EXPERIMENTAL
Intervention: pancuronium 0.01 mg/kg
Number of subjects: 40
Study 6258375 — intervention group
Group type: EXPERIMENTAL
Intervention: pancuronium 0.015 mg/kg
Number of subjects: 40
Study 6258375 — intervention group
Group type: EXPERIMENTAL
Intervention: gallamine 0.3 mg/kg
Number of subjects: 40
Study 6258375 — intervention group
Group type: EXPERIMENTAL
Intervention: gallamine 0.4 mg/kg
Number of subjects: 40
Study 29947813 — intervention group
Group type: EXPERIMENTAL
Intervention: Susceptibility Vessel Sign (SVS+)
Number of subjects: 287
Study 29047376 — intervention group
Group type: EXPERIMENTAL
Intervention: Women's education (primary education)
Number of subjects: 0
Study 29047376 — intervention group
Group type: EXPERIMENTAL
Intervention: Women's education (secondary education)
Number of subjects: 0
Study 29047376 — intervention group
Group type: EXPERIMENTAL
Intervention: Women's education
Number of subjects: 0
Study 29047376 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher women's education
Number of subjects: 0
Study 29047376 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher mother's education (primary)
Number of subjects: 0
Study 29047376 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher mother's education (secondary)
Number of subjects: 0
Study 29047376 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher men's education
Number of subjects: 0
Study 29047376 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher education of any household member
Number of subjects: 0
Study 29047376 — intervention group
Group type: EXPERIMENTAL
Intervention: Households where mother's education was better than the best-educated man
Number of subjects: 0
Study 25856682 — intervention group
Group type: EXPERIMENTAL
Intervention: 1600 μg of salbutamol
Number of subjects: 20
Study 25856682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 23954900 — intervention group
Group type: EXPERIMENTAL
Intervention: Assay-sensitive regimen
Number of subjects: 262
Study 23954900 — intervention group
Group type: COMPARATOR
Intervention: Assay-intermediate and resistant groups (I+R)
Number of subjects: 262
Study 21046356 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapamycin monotherapy (0.1 mg/kg; target trough levels 8-10 ng/ml; 26-314 days)
Number of subjects: 22
Study 21046356 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapamycin monotherapy
Number of subjects: 22
Study 21046356 — intervention group
Group type: COMPARATOR
Intervention: Control (14 patients waiting for islet transplant without rapamycin pre-conditioning)
Number of subjects: 22